Literature DB >> 21252839

Haemodialysis catheters.

Jacek Wadełek1.   

Abstract

Haemodialysis central venous catheters are commonly being introduced in patients requiring emergency or chronic renal replacement therapy. There are two main categories of haemodialysis catheters: 1. Non-tunnelled, uncuffed, designed for short-term venous access of up to three weeks. They are, made of stiff materials such as polyurethane or polyvinyl. 2. Tunnelled, cuffed catheters. They are usually made of silicone, silastic elastomeric, or carbothane, are much softer and can be used for both temporary and permanent access. The latter catheters are usually inserted via peel-away sheaths, introduced using the Seldinger technique. Unlike surgically implanted devices, they can be used immediately after correct placement under fluoroscopy. The paper reviews catheters currently available, including discussion of materials, design, vascular access sites, and possible complications.

Entities:  

Mesh:

Year:  2010        PMID: 21252839

Source DB:  PubMed          Journal:  Anestezjol Intens Ter        ISSN: 0209-1712


  3 in total

1.  Characteristics and 3-year mortality and infection rates among incident hemodialysis patients with a permanent catheter undergoing a first vascular access conversion.

Authors:  Yee-Yung Ng; Yen-Ni Hung; Shiao-Chi Wu; Po-Jen Ko
Journal:  Clin Exp Nephrol       Date:  2013-06-12       Impact factor: 2.801

2.  Pseudo-arterial Temporary Hemodialysis Catheter Placement in the Left Internal Jugular Vein Ipsilateral to a Preexisting Brachio-axillary Arteriovenous Graft.

Authors:  Macaulay Amechi Chukwukadibia Onuigbo; Nneoma Agbasi; Bibek Sarki; Sana Khan; Kramer Wahlberg
Journal:  Indian J Nephrol       Date:  2019-12-27

3.  Tunnelled haemodialysis catheter and haemodialysis outcomes: a retrospective cohort study in Zagreb, Croatia.

Authors:  Vedran Pašara; Bojana Maksimović; Mihaela Gunjača; Karlo Mihovilović; Andrea Lončar; Boris Kudumija; Igor Žabić; Mladen Knotek
Journal:  BMJ Open       Date:  2016-05-17       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.